Mission of AIM with Immunotherapy
Our mission is to provide healthcare providers with the latest immunotherapy knowledge and resources to help patients achieve the best possible outcomes. Through education, resource sharing, and continual updates on new FDA-approved treatments, AIM with Immunotherapy is committed to ensuring that you have access to the most current information in the field of cancer immunotherapy.
AIM with Immunotherapy broadly defines immunotherapeutic agents as those that:
- seek to enhance or suppress the immune system response;
- regenerate immune recognition of foreign antigens;
- interfere with checkpoint controls; and/or
- comprise molecules stemming from the natural immunology.
These agents currently include antibody-drug conjugates, bispecific antibodies, CAR T-cell therapy, cytokines/immune system modulators, immune checkpoint inhibitors, monoclonal antibodies, tumor-infiltrating lymphocytes, and vaccines. There are likely to be other agents created to fight cancer that will also fit under the broad description of immunotherapy, and as they are approved, we will add information about them to this website.
Education about Immunotherapies
There is a need for knowledge transfer from experts within the oncology academic centers and researchers throughout the country to community-based practitioners and clinicians now utilizing immune-based therapies across many different tumor types. Each year, new and innovative immunotherapy agents receive FDA approval. This site is dedicated to updating professionals about these topics.
Provider Recognition and Management of Immune-Related Adverse Effects (irAEs)
As immune checkpoint inhibitors are employed in a wider array of tumor types, a range of irAEs are being recognized. Some of these toxicities can be difficult to diagnose, complex to manage, and potentially persistent throughout a patient’s life. A key goal of this website is to engage healthcare providers to optimally address irAEs, with a focus on contextual issues within the tumor types.
Resources for Providers to Use with Their Patients
This website offers patient education materials that providers can share with their patients. Patient education will allow patients to become proactive members of the oncology team in terms of irAE recognition and management. With the achievement of this goal, AIM with Immunotherapy will help improve therapeutic outcomes for patients receiving immunotherapy for the treatment of their cancer.